TIBET AIM PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 81.7633 million yuan, an increase of 95.52%
TIBET AIM PHARM released its third-quarter report for 2025, with operating revenue of 489 million yuan in the first three quarters, a year-on-year decrease of 4.65%. The net profit attributable to shareholders of the listed company was 81.7633 million yuan, a year-on-year increase of 95.52%. The net profit after deducting non-recurring gains and losses was 39.9473 million yuan, a year-on-year increase of 144.50%. The basic earnings per share were 0.44 yuan
According to the Zhitong Finance APP, TIBET AIM PHARM (002826.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 489 million yuan, a year-on-year decrease of 4.65%. The net profit attributable to shareholders of the listed company was 81.7633 million yuan, a year-on-year increase of 95.52%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 39.9473 million yuan, a year-on-year increase of 144.50%. The basic earnings per share were 0.44 yuan
